SCHEMBL1102089

SCHEMBL1102089

CC(C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1)n1ccc2cc(F)ccc21

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.55
KMT2A Q03164 9/20 0.55
TDP1 Q9NUW8 2/20 0.55
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 1/20 0.55
POLB P06746 4/20 0.53
SCN3A Q9NY46 2/20 0.52
SCN1A P35498 1/20 0.52
SCN4A P35499 1/20 0.52
SCN5A Q14524 1/20 0.52
SCN9A Q15858 1/20 0.52
SCN2A Q99250 1/20 0.52
SCN8A Q9UQD0 1/20 0.52
SCN10A Q9Y5Y9 1/20 0.52
CA1 P00915 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102114 0.90 KMT2A (0.61) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL1091270 0.90 MEN1 (0.60) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL1102265 0.88 KMT2A (0.61) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL9972284 0.87 MEN1 (0.56) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL1102057 0.84 MEN1 (0.60) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL1102135 0.84 ALDH1A1 (0.53) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL1102264 0.83 TDP1 (0.56) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL1102107 0.83 TDP1 (0.55) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL13821540 0.82 MEN1 (0.45) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL9974115 0.81 MEN1 (0.58) MEN1KMT2ATDP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 US disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 US disclosed
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 MEN1 2329/4885KMT2A 3111/4885TDP1 2356/4885
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels SCNN1G, KCNN3, KCNN2 MEN1 2329/4885KMT2A 3111/4885TDP1 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.